Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel-group Treatment, Phase 2, Double-blind, Three-arm Study to Assess Efficacy and Safety of Finerenone Plus Empagliflozin Compared With Either Finerenone or Empagliflozin Alone in Participants With Chronic Kidney Disease and Type 2 Diabetes.

NCT05254002 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT05254002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05254002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel-group Treatment, Phase 2, Double-blind, Three-arm Study to Assess Efficacy and Safety of Finerenone Plus Empagliflozin Compared With Either Finerenone or Empagliflozin Alone in Participants With Chronic Kidney Disease and Type 2 Diabetes.
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
June 23, 2022
Completion date
March 17, 2025
Enrollment
1,664 (actual)
Sites
173

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, type 2 diabetes mellitus